CASE REPORT

A case of CRPC with multiple bladder invasions treated with EBRT followed by HDR-BT boost

1,2,3YOSHIAKI TAKAGAWA, MD and 3JUN ITAMI, MD, PhD
1Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Fukushima, Japan
2Department of Radiology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
3Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan

Address correspondence to: Dr Yoshiaki Takagawa
E-mail: yoshiaki.takagawa@rad.med.keio.ac.jp

INTRODUCTION

The optimal timing of radiotherapy after prostatectomy was unknown until the recent RADICALS-RT study showed that salvage radiotherapy is less toxic than adjuvant radiotherapy.1 The RAVES and GETUG-AFU 17 studies also reported a higher incidence of genitourinary (GU) toxicity in the adjuvant radiotherapy group.2,3 The National Comprehensive Cancer Network (NCCN) guidelines recommend adjuvant or salvage radiotherapy after prostatectomy at 64–72 Gy via external beam radiotherapy (EBRT) in standard fractions.4 However, the American Urological Association/American Society for Radiation Oncology guidelines for adjuvant and salvage radiotherapy after prostatectomy do not mention high-dose-rate brachytherapy (HDR-BT) in the context of salvage radiotherapy.5

Gross recurrent tumors in the prostate bed have occasionally been reported after prostatectomy. The NCCN guidelines state that biopsy-proven gross recurrence may require higher treatment doses. If a recurrent tumor is detected macroscopically on multiple imaging studies, EBRT plus HDR-BT boost may allow higher doses to be delivered than EBRT alone.

We report a case of post-operative local recurrence of castration-resistant prostate cancer with multiple bulky bladder invasions treated using EBRT followed by a high-dose-rate brachytherapy (HDR-BT) boost. The EBRT dose was 46 Gy delivered in 23 fractions with intensity-modulated radiotherapy to the entire pelvis. The HDR-BT dose was 15 Gy delivered in 1 fraction using ultrasound, CT, and MRI-guided brachytherapy with 18 interstitial needles. We achieved excellent local control of cancer in the prostate bed and multiple bulky bladder invasions. EBRT plus HDR-BT boost can allow higher doses to be delivered than EBRT alone for locally recurrent bulky prostate cancer following prostatectomy.

CLINICAL PRESENTATION

A 69-year-old male was diagnosed with high-risk prostate cancer with a Gleason score of 9 (4 + 5) based on a prostate biopsy performed in 2006. The initial prostate-specific antigen (PSA) level was 9.8 ng ml⁻¹, and the clinical stage was T3N0M0. Definitive, robot-assisted, radical prostatectomy revealed the pathological stage to be T3N0M0 with a Gleason score of 9 (5 + 4). This primary surgery was performed at another hospital. Therefore, the details regarding pathological features (e.g. pR0 or pR1 resection) were unfortunately unavailable in our medical records. The post-operative PSA nadir was also unknown. 1 year after prostatectomy, his PSA level increased by 0.946 ng ml⁻¹, and he was diagnosed with failure of prostatectomy. Salvage hormonal therapy (bicalutamide and leuprorelin acetate) was administered. After 4 years of hormonal therapy, the PSA level was <0.008 ng ml⁻¹. However, he stopped hormonal therapy for 7 months, and his PSA level increased to 1.362 ng ml⁻¹, following which, hormonal therapy was restarted. Nevertheless, the PSA level gradually increased from 2.974 ng ml⁻¹ in 2015 to 4.833 ng ml⁻¹ in 2016. Thereafter, he presented to our hospital (National Cancer Center Hospital) for treatment. He was diagnosed with CRPC in 2017.

CT revealed local recurrence of the tumor in the prostate bed. Enzalutamide was administered, but the tumor continued to grow. Multiple bulky bladder invasions were visualized on
CT after 1 year (Figure 1A). The patient complained of dysuria, hematuria, and urinary incontinence. He refused chemotherapy and was referred to the Department of Radiation Oncology for salvage radiotherapy. Restaging fluorodeoxyglucose-positron emission tomography (FDG-PET)/magnetic resonance imaging (MRI) showed no distant metastases. Cystoscopy and biopsy of the bladder tumor (Figure 1B) confirmed adenocarcinoma with a Gleason score of 9 (4 + 5).

**TREATMENT**

EBRT alone was considered insufficient for controlling the recurrent tumors, given the extent of the disease. Thus, we decided to perform EBRT with intensity-modulated radiotherapy (IMRT) followed by an HDR-BT boost. Before EBRT, we inserted a hydrogel spacer (SpaceOAR®, Boston Scientific, Marlborough, MA) between the prostate bed and rectum to reduce the rectal dose. The maximum PSA level before radiotherapy was 31.723 ng ml⁻¹. The EBRT dose was 46 Gy, delivered in 23 fractions to the entire pelvis. 6 days after the completion of EBRT, MRI showed that although there was slight shrinkage, the recurrent tumor remained bulky. 2 weeks after the completion of EBRT, HDR-BT was performed. The prescribed dose was 15 Gy in 1 fraction. For remote afterloading, we used microSelectron HDR-V3 with Oncentra Brachy (Elekta, Sweden) with Ir-192. We inserted 18 ProGuide Sharp Needles (Elekta, Sweden) with an outer diameter of 1.67 mm into the tumor under local anesthesia and transrectal ultrasound (TRUS) guidance (Figure 2). During needle implantation, we performed a CT scan to optimize the positions and depths of the needles. Second, after needle implantation, planning CT and MRI were performed. The acquired MRI were fused to the planning CT, and we contoured the target and organ-at-risk on the treatment planning system (Figure 3). If any needle was slightly shallower or deeper than planned on MRI, we modified its depth to achieve the position as per the planning CT. We contoured the tumor in the bladder neck and prostate bed to determine the clinical target volume (CTV), which was 58.35 cc. We applied the dose constraints of HDR monotherapy for prostate cancer according to our institutional protocol. Table 1 lists the dosimetric parameters and dose constraints. The total biological effective dose of EBRT plus HDR-BT was 272 Gy, assuming an α/β ratio of 1.5.

3 months after HDR-BT, the PSA level decreased to 6.970 ng ml⁻¹, and cystoscopy showed a reduction in bladder invasion (Figure 4). Acute toxicities included Grade 1 dysuria and Grade 1 hematuria, which pre-existed and did not worsen after radiotherapy. However, 4 months after HDR-BT, the PSA level increased again, and multiple bone metastases were detected. The patient experienced numbness and weakness in his left hand. We administered palliative EBRT at a dose of 46 Gy in 23 fractions for vertebral metastasis. Thereafter, his symptoms resolved, and the PSA level decreased slightly.

At 9 months after HDR-BT, MRI revealed significant shrinkage of the multiple bladder invasions (Figure 5). The patient was unable to retain urine before or after radiotherapy, and his maximum bladder volume was approximately 50 ml. Therefore, we placed a urinary catheter to fill the bladder with saline during MRI examinations. Dysuria and hematuria resolved 1 year after HDR-BT. Late toxicities included Grade 1 urinary incontinence (which pre-existed and did not worsen after radiotherapy) and Grade 1 bloody stool. At 22 months after HDR-BT, the patient had Grade 1 urinary incontinence without hematuria and Grade 1 bloody stool. He continued receiving enzalutamide, but his PSA level continued to increase during follow-up. However, there was no urinary obstruction requiring nephrostomy or ureteral stent placement.
DISCUSSION

We achieved excellent local control of post-operative local recurrence of CRPC with multiple bulky bladder invasions using EBRT followed by an HDR-BT boost. In the present case, the CTV at the time of brachytherapy was 58.35 cc, indicating a very bulky tumor. To the best of our knowledge, the present report is the first to demonstrate the excellent local control of bulky local recurrence of prostate cancer.

Most adjuvant and salvage radiotherapies use EBRT alone because the target is unclear. Dose escalation protocols for EBRT with IMRT have achieved better tumor control rates. However, these treatments have been associated with higher grade GU toxicities such as bladder neck and vesicourethral anastomosis. HDR-BT can achieve dose escalation for the gross target while limiting toxicities in the adjacent organs, such as the urethra and rectum, within tolerable levels.

Radiobiologically, prostate cancer has a low α/β ratio; hence, hypofractionation schedules such as HDR-BT have a significantly greater biological effect than EBRT. The ASCENDE-RT trial showed that the rate of biochemical-progression-free survival was significantly higher with low-dose-rate prostate brachytherapy boost than that with 78 Gy EBRT. Approximately, 70% of the patients included in this trial had NCCN high-risk prostate cancer. Although no high-level randomized trial has compared HDR boost with EBRT alone for salvage treatment in local recurrence after prostatectomy, we hypothesized the same scenario as the ASCENDE-RT trial.

Recent advances in imaging methods, such as multiparametric MRI and choline PET/CT, enable the detection of local and distant recurrences. More recently, prostate-specific membrane antigen PET-CT has emerged as a new, standard imaging modality, not only for determining the recurrence status, but also for the initial treatment of prostate cancer. Owing to these recent advances, local recurrence of prostate cancer after initial treatment can be detected at higher frequencies.

There are very few reports of salvage HDR-BT for recurrent prostate cancer after radical prostatectomy. Niehoff et al. treated 35 patients with TRUS-detectable recurrent tumors after radical
prostatectomy using HDR-BT combined with EBRT (3D-CRT technique). They administered a BT boost (30 Gy in 2 fractions) after complementary EBRT in which 21 and 14 patients received a dose of 30 Gy and 40 Gy, respectively. This report did not indicate the CTV. After a mean follow-up of 27 months, 67% of the patients had elevated PSA levels with or without local recurrence and/or systemic progress. The mean duration of absence of biochemical evidence of disease was 12 months. There was no significant difference between patients who received 30 Gy EBRT and those who received 40 Gy EBRT. The study also found no acute or late Grade III/IV toxicity in any of the patients (LENT-SOMA, RTOG/EORTC).

Strom et al. reported six patients with biopsy-proven recurrent prostate cancer after definitive prostatectomy treated with or without IMRT. Five patients received IMRT at a dose of 45–50.4 Gy in 25–28 fractions to the prostate bed followed by HDR-BT (19 Gy/2 fractions). The sixth patient received HDR-BT monotherapy at a dose of 38.5 Gy in four fractions over 3 days. The median CTV was 2.3 cc (range: 1.6–4.7 cc). The median follow-up period was 9 months, and at the last follow-up, all patients had undetectable PSA levels. One patient experienced late Grade 2 urinary incontinence. There were no cases of late gastrointestinal toxicity ≥Grade 2.

Buchser et al. reported 11 patients who received salvage HDR-BT (15 Gy/1 fraction) with EBRT (37.5 Gy/15 fractions) for histologically confirmed, locally relapsed macroscopic prostate cancer after radical prostatectomy with a median volume of 3.34 cc (range: 1.98–6.76 cc). At a median follow-up of 7 months, all patients showed an appropriate biochemical response, and the acute GU/gastrointestinal toxicity levels were acceptable; there were no cases of late toxicity.

Compared to the outcomes in the abovementioned studies, in the present case we achieved excellent local control of a very bulky tumor involving the bladder (CTV: 58.35 cc) using EBRT plus HDR-BT boost. EBRT plus HDR-BT boost allows higher doses to be administered than EBRT alone, and is associated with less toxicity even when treating bulky, locally recurrent prostate cancer following prostatectomy. Unfortunately, our patient developed multiple bone metastases 4 months after radiotherapy. Although we performed an FDG-PET scan to exclude distant metastasis at the time of initial radiotherapy, there may have been micrometastatic lesions before radiotherapy. As a result, our treatment may have been palliative, but not definitive. Recently, the STAMPEDE trial showed that palliative radiotherapy for the primary site had a significant benefit for overall survival in patients with prostate cancer with low metastatic burden. Therefore, even after palliative treatment, strong local control to prevent urinary obstruction is important in terms of patients' quality of life.

Urinary obstruction is a major complication of advanced prostate cancer. Treatment for malignant ureteric obstructions includes percutaneous nephrostomy, ureteric stent insertion, or occasionally, other forms of urinary diversion. New et al. reviewed 184 patients who underwent percutaneous nephrostomy due to prostate cancer progression. They reported a survival after percutaneous nephrostomy of 4–31 months, with longer survival typically seen in patients who were hormone naïve or those who experienced good recovery of their renal function. Percutaneous nephrostomy is very effective for treating malignant urinary obstructions, but procedure-related complications necessitate frequent readmission. Nephrostomy may also influence patients' physical activity levels and restrict their social lives. Therefore, a long-term follow-up is required. At 22 months after HDR-BT, our patient had Grade 1 urinary incontinence due to late toxicity of radiotherapy, but is being continuously followed-up.

Our study has some limitations. First, there was a lack of initial perioperative findings. Second, although we used TRUS-, CT-, and MRI-guided brachytherapy to increase the accuracy of the needle insertions, the possibility of needle movement resulting in a slightly deeper insertion or needle removal during irradiation cannot be denied. Third, although EBRT plus HDR-BT boost is a potent local treatment, its long-term and late toxicities are unknown. Therefore, a long-term follow-up is required. At 22 months after HDR-BT, our patient had Grade 1 urinary incontinence and Grade 1 tarry stools. Currently, the patient is without any treatment and has not needed readmission due to late toxicity of radiotherapy, and is being continuously followed-up.

We achieved excellent local control of cancer in the prostate bed and multiple bulky bladder invasions. EBRT plus HDR-BT boost can allow higher doses to be delivered than EBRT alone for locally recurrent bulky prostate cancer following prostatectomy. However, treatment toxicity and indication of EBRT + HDR-BT boost should be thoroughly discussed considered among radiation oncology experts.

**LEARNING POINTS**
- EBRT followed by HDR-BT boost can enable control of bulky recurrence in the prostate bed and CRPC bladder invasion after prostatectomy.
- If the treatment is palliative, local control to prevent urinary obstruction is important in terms of the patient’s quality of life.

**ACKNOWLEDGMENT**
We would like to thank Editage (www.editage.com) for English language editing.

**CONTRIBUTORS**
YT conceptualized the project and obtained the data used for the study. All authors contributed to data analysis and editing of the article.

**CONSENT**
Written informed consent was obtained from the patient for publication of this case report and accompanying images.
REFERENCES

1. Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (Radicals-RT): a randomised, controlled phase 3 trial. *Lancet* 2020; 396: 1413–21. doi: https://doi.org/10.1016/S0140-6736(20)31553-1

2. Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjunctive radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. *Lancet Oncol* 2020; 21: 1331–40. doi: https://doi.org/10.1016/S1470-2045(20)30456-3

3. Sargos P, Chabaud S, Latorella I, Magné N, Benyoucef A, Supiot S, et al. Adjunctive radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. *Lancet Oncol* 2020; 21: 1341–52. doi: https://doi.org/10.1016/S1470-2045(20)30454-X

4. National Comprehensive Cancer Network. Prostate cancer guidelines. 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf [25 May 2021].

5. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. *J Urol* 2013; 190: 441–9. doi: https://doi.org/10.1016/j.juro.2013.05.032

6. De Meerleer G, Fonteyne V, Meerschout NM, et al. Salvage radiotherapy: a plea for dose-escalation and intensity-modulated radiotherapy. *Eur J Cancer* 2012; 48: 1415–6. doi: https://doi.org/10.1016/j.ejca.2012.01.024

7. Morton G. The best method for dose escalation: prostate brachytherapy. *Can Urol Assoc J* 2012; 6: 196–8. doi: https://doi.org/10.1458/cuaj.12121

8. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? *Int J Radiat Oncol Biol Phys* 2001; 50: 1021–31. doi: https://doi.org/10.1016/s0360-3016(01)01607-8

9. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. *Int J Radiat Oncol Biol Phys* 2017; 98: 275–85. doi: https://doi.org/10.1016/j.ijrobp.2016.11.026

10. Netley M, Yu J, Fulcher AS, Turner MA, Cockrell CH, Nguyen D. Pictorial review. diagnosis of recurrent prostate cancer and its mimics at multiparametric prostate MRI. *Br J Radiol* 2015; 88: 20150362. doi: https://doi.org/10.1259/bjr.20150362

11. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. 18 F- fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. *Lancet Oncol* 2019; 20: 1286–94. doi: https://doi.org/10.1016/S1470-2045(19)30415-2

12. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. 68Ga-PSMA-11 PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. *Lancet Oncol* 2019; 20: 1286–94. doi: https://doi.org/10.1016/S1470-2045(19)30415-2

13. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. *JAMA Oncol* 2019; 5: 856–63. doi: https://doi.org/10.1001/jamaoncol.2019.0096

14. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-Specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. *Lancet* 2020; 395: 1208–16. doi: https://doi.org/10.1016/S0140-6736(20)30314-7

15. Niehoff P, Loch T, Nürnberg N, Galalae R, Egberts J, Kohr P, et al. Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy. *Brachytherapy* 2005; 4: 141–5. doi: https://doi.org/10.1016/j.brachy.2004.12.004

16. Strom Tj, Wilder RB, Fernandez DC, Mellon EA, Sani AS, Hunt DC, et al. High-dose-rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy. *Brachytherapy* 2014; 13: 123–7. doi: https://doi.org/10.1016/j.brachy.2013.09.008

17. Buchser D, Gomez-Iturriaga A, Melcon JIR, Casquero E, Llarena R, Cacicedo J, et al. Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy. *J Contemp Brachytherapy* 2016; 8: 477–83. doi: https://doi.org/10.5114/jcb.2016.64441

18. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. *Lancet* 2018; 392: 2353–66. doi: https://doi.org/10.1016/S0140-6736(18)32486-3

19. New F, Deverill S, Somani BK. Role of percutaneous nephrostomy in end of life prostate cancer patients: a systematic review of the literature. *Cent European J Urol* 2018; 71: 404–9. doi: https://doi.org/10.5173/ceju.2018.1780

20. Bigum LH, Spielmann ME, Juhl G, Rasmussen A. A qualitative study exploring male cancer patients’ experiences with percutaneous nephrostomy. *Scand J Urol* 2015; 49: 162–8. doi: https://doi.org/10.3109/21681805.2014.938694